Mallinckrodt receives a complete response letter from the u.s. fda for terlipressin

Mallinckrodt receives a complete response letter from the u.s. food and drug administration (fda) for terlipressin for the treatment of hepatorenal syndrome type 1 (hrs-1).mallinckrodt plc - crl stated that, based on available data, agency cannot approve terlipressin nda in its current form.mallinckrodt plc - crl stated fda requires more information to support positive risk-benefit profile for terlipressin for patients with hrs-1.mallinckrodt plc - "surprised by and disagree with fda's decision".
MNK Ratings Summary
MNK Quant Ranking